

Current Status of the Implication of the Clinical Practice Pattern in Hemodialysis Prescription in Regular Hemodialysis Patients in Egypt (Qalyubia)

THESIS

Submitted For Partial Fulfillment of Master Degree In
Internal Medicine

Presented by

Mohamed Abo Attab Nasr
M.B.B.CH Zagazig University

Under Supervision of

Prof. Dr. Mohamed El-Tayeb Nasser
Professor of Internal Medicine& nephrology
Faculty of Medicine
Ain Shams University

Dr. Waleed Anwar Abd El Mohsen
Assistant professor of Internal Medicine& nephrology
Faculty of Medicine
Ain Shams University

Faculty of Medicine
Ain Shams University

2014



Acknowledgement

First and foremost thanks to ALLAH who granted me the power to accomplish this work.

*I would like to express my deep gratitude and appreciation to **Prof. Dr. Mohamed El-Tayeb Nasser** Professor of Internal Medicine& nephrology , Faculty of Medicine, **Ain Shams University**, for his kind supervision and support. Without his continuous guidance and encouragement, this thesis would have never seen light.*

*I am sincerely grateful to **Dr.Waleed Anwar Abd El Mohsen** Assistant professor of Internal Medicine& nephrology Faculty of Medicine Ain Shams University. Every step and every detail in this work have been kindly assisted and supported by his effort and care.*

Last but not the least; I would like to thank my family , my wife and my friends for supporting me spiritually throughout this journey.

Contents

List of figures, tables and abbreviations-----	II
Introduction -----	1
Aim of the work-----	2
Review of literature -----	3
Hemodialysis prescription -----	3
Hemodialysis-associated comorbidities -----	18
Guidelines for kidney diseases -----	24
Hemodialysis in Egypt -----	30
Patients and methods -----	32
Statistical analysis -----	36
Results -----	38
Discussion -----	78
Summary and conclusion-----	86
Recommendations -----	90
References-----	91
Arabic summary -----	

List of figures

Figure (1): Hemodialysis in progress -----	4
Figure (2): Hemodialysis machine -----	4
Figure (3): Dialyzer -----	8
Figure (4): A radiocephalic fistula -----	16
Figure (5): Age distribution in the study population -----	38
Figure (6): Gender distribution in the study population -----	39
Figure (7): Different causes of CKD in the study population ---	40
Figure (8): Hypertension in the study population-----	41
Figure (9): Frequency of diabetes mellitus in the study population--	42
Figure (10): Frequency of ischemic heart disease presence in the study population -----	43
Figure (11): Chronic liver disease in the study population -----	44
Figure (12): Chronic obstructive pulmoanry disease in the study population -----	45
Figure (13): Chronic arthropathy in the study population-----	46
Figure (14): Frequency of PVD presence in the study population	47
Figure (15): Work status in the study population	48
Figure (16): Dependency and wheel chair status in the study population -----	49
Figure (17): Frequency of dialysis in the study population -----	50
Figure (18): Duration of dialysis in the study population -----	51
Figure (19): Sponsoring status in the study population -----	52
Figure (20): Type of vascular access in the study population ---	53
Figure (21): Frequency of failed access in the study population	54

Figure (22): The levels of hemoglobin during the study -----	55
Figure (23): History of blood transfusion in the study population	56
Figure (24): Different types of ESA used by the study population	57
Figure (25): History of iron injection in the study population --	58
Figure (26): History of vitamin B complex use in the study population -----	59
Figure (27): History of L-carnitine use in the study population-	60
Figure (28): History of vitamin D use in the study population--	61
Figure (29): The serum levels of calcium during the study ----	62
Figure (30): The levels of phosphate during the study -----	63
Figure (31): Calcium category in the study population-----	64
Figure (32): Phosphorus level in the study population -----	65
Figure (33): The levels of $\text{Ca} \times \text{PO}_4$ product during the study--	66
Figure (34): Different types of phosphorus binders used by the study population -----	67
Figure (35): Hypotension during HD session in the study population	68
Figure (36): Cramps during HD session in the study population	69
Figure (37): Bony aches during HD session in the study population	70
Figure (38): Itching during HD session in the study population	71
Figure (39): Hepatitis C virus -----	72
Figure (40): Hepatitis B virus -----	73
Figure (41): Types of dialyzers used in the study population ---	74
Figure (42): Sterilization of dialyzers used in the study population	75
Figure (43): Dialzyer surface area distribution in the study population -----	76
Figure (44): Criteria of dialysate used in study population-----	77

List of tables

Table (1): Data collection sheet for hemodialysis prescription in Egypt study -----	33
Table (2): Age distribution in the study population-----	38
Table (3): Gender distribution in the study population -----	39
Table (4): Different causes of CKD in the study population ----	40
Table (5): Hypertension in the study population-----	41
Table (6): Diabetes mellitus in the study population -----	42
Table (7): Ischemic heart disease in the study population -----	43
Table (8): Chronic liver disease in the study population -----	44
Table (9): Chronic obstructive pulmoanry disease in the study population -----	45
Table (10): Chronic arthropathy in the study population -----	46
Table (11): PVD in the study population -----	47
Table (12): Work status in the study population-----	48
Table (13): Dependency and wheel chair status in the study population -----	49
Table (14): Dialysis in the study population -----	50
Table (15): Duration of dialysis in the study population -----	51
Table (16): Sponsoring status in the study population-----	52
Table (17): Type of vascular access in the study population ----	53
Table (18): Failed access in the study population-----	54
Table (19): The levels of hemoglobin during the study -----	55
Table (20): History of blood transfusion in the study population	56
Table (21): Different types of ESA used by study population---	57

Table (22): History of iron injection in the study population----	58
Table (23): History of vitamin B complex use in the study population -----	59
Table (24): History of L-carnitine use in the study population --	60
Table (25): History of vitamin D use in the study population ---	61
Table (26): The serum levels of calcium during the study -----	62
Table (27): The levels of phosphate during the study -----	63
Table (28): Calcium category in the study population-----	64
Table (29): Phosphorus category in the study population -----	65
Table (30): The levels of Ca x PO ₄ product during the study ---	66
Table (31): Different types of phosphorus binders used by the study population -----	67
Table (32): Hypotension during HD session in the study population	68
Table (33): Cramps during HD session in the study population	69
Table (34): Bony aches during HD session in the study population	70
Table (35): Itching during HD session in the study population	71
Table (36): Hepatitis C virus -----	72
Table (37): Hepatitis B virus -----	73
Table (38): Isolation of hepatitis B virus patients and hepatitis C virus patients in study population -----	73
Table (39): Types of dialyzers used in the study population ----	74
Table (40): Sterilization of dialyzers used in the study population	75
Table (41): Dialzyer surface area distribution in the study population	76
Table (42): Criteria of dialysate used in study population-----	77

List of abbreviations

AV	:	Arteriovenous
CAPD	:	Continuous Ambulatory Peritoneal Dialysis
CHOIR	:	Correction of Hemoglobin and Outcomes in Renal insufficiency
CKD	:	Chronic Kidney Disease
CMB	:	Calcium Mass Balance
CVD	:	Cardiovascular Disease
D Ca	:	Dialysate Calcium concentration
DOPPS	:	Dialysis Outcomes and Practice Patterns Study
DOQi	:	Dialysis Outcome Quality initiative
eKt/V	:	Equilibrated Kt/V
ERA/EDTA	:	European Renal Association-European Dialysis and Transplantation Association
ESAs	:	Erythropoietin Stimulating Agents
FDA	:	Food and Drug Administration
FGF	:	Fibroblast Growth Factor
GraDe	:	Grades of recommendation assessment, Development, and evaluation
HD	:	Hemodialysis
HDF	:	Hemodiafiltration

iCa	:	Ionized calcium
IHDF	:	Intermittent on-line Hemodiafiltration
IL	:	Interleukin
iPTH	:	Intact Parathyroid Hormone
LVH	:	Left Ventricular Hypertrophy
MBD	:	Mineral and Bone Disorder
MIA	:	Malnutrition-Inflammation Atherosclerosis
MPO	:	Membrane Permeabilities Outcomes
nPCR	:	Normalized Protein Catabolic Rate
PEM	:	Protein-Energy Malnutrition
PTH	:	Parathyroid Hormone
stKt/V	:	Standard Kt/V
SRI	:	Solute Removal Index
β₂m	:	beta-2-microglobulin
K/DOGI	:	Kidney Disease Outcome Quality Initiative.
ADPKD	:	Autosomal Dominant Polycystic Kidney Disease
SLE	:	Systemic Lupus Erythromatosis
GN	:	Glomerulonephritis
PVD	:	Peripheral Vascular Disease
TNF	:	Tumour Necrosis Factor
CARI	:	Australian and Newzland Society Of Nephrology
NKF	:	National Kidney Foundation

BMI	:	Body Mass Index
stKt/V	:	Standard Kt/V
SRI	:	Solute Removal Index

Introduction

Hemodialysis (HD) is the routine renal replacement therapy for more than 300,000 patients in the United States who have reached end-stage renal disease. The goals of HD are straightforward and include restoring the body's intracellular and extracellular fluid environment and accomplishing solute balance by either removal from the blood into the dialysate or from the dialysate into the blood. Optimal care of the patient receiving long-term HD requires appropriate prescription according to patient- and device-dependent variables (*Ikizler and Schulman, 2005*).

Patients who have ESRD and are on HD are characterized by an exceptionally high mortality rate compared with the general population (*Ajiro, 2007*).

The state of health of individuals with kidney failure who are initiated on dialysis, and therefore their earlier care, is a major determinant of survival and wellbeing on maintenance dialysis, and that persons with kidney disease are more likely to die from cardiovascular disease than to reach dialysis; hence, the urgency to focus on early detection and treatment in all high-risk populations (*Locatelli, 2008*).

Aim of the work

The aim of this work is to Study the pattern of current clinical practice in hemodialysis prescription in regular hemodialysis patients in Egypt and compare this pattern with standard international guidelines in hemodialysis prescription (*K/DOQI, 2010*), stressing on anemia, bone disease management and adequacy of dialysis.

State the current status of dialysis patient in Egypt (questionnaire).

Hemodialysis prescription

Hemodialysis (HD) is the routine renal replacement therapy for more than 300,000 patients in the United States who have reached end-stage renal disease. The goals of HD are straightforward and include restoring the body's intracellular and extracellular fluid environment and accomplishing solute balance by either removal from the blood into the dialysate or from the dialysate into the blood. Optimal care of the patient receiving long-term HD requires appropriate prescription according to patient- and device-dependent variables (*Ikizler and Schulman., 2005*).

Hemodialysis can be an outpatient or inpatient therapy. Routine hemodialysis is conducted in a dialysis outpatient facility, either a purpose built room in a hospital or a dedicated, stand alone clinic. Less frequently hemodialysis is done at home. Dialysis treatments in a clinic are initiated and managed by specialized staff made up of nurses and technicians; dialysis treatments at home can be self initiated and managed or done jointly with the assistance of a trained helper who is usually a family member (*Abel et al., 2013*).

A dialysis machine pumps small amounts of blood out of the body and through a filter called an artificial kidney or dialyzer. This kidney filters extra fluid and wastes from the blood. The blood is then pumped back into body (*Abel et al., 2013*).

The dialyzer, or filter, has two parts; one part for blood and the other part for a washing fluid called dialysate. A thin membrane separates these two sides. Blood cells, protein and other important things remain in blood because they are too big to pass through the membrane. Smaller waste products such as urea, creatinine and extra fluid pass through the

membrane and are removed. Changes in the dialysate or cleansing fluid can be made for special needs (*Abel et al., 2013*).



Figure (1): Hemodialysis in progress (*Abel et al., 2013*).



Figure (2): Hemodialysis machine (*Abel et al., 2013*).